Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.
With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...
Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based ...
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN ...
At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...
Hilton Head Island Packet on MSN
With no vaccine, this virus may spike in SC alongside other winter illnesses. Here’s what to know
As flu and other winter illnesses rise, another contagious virus often spreads each season. Here’s what to know about ...
Hundreds of Boston residents and some Boston University students who ended up in the emergency room with the norovirus this winter may take comfort in a recent research breakthrough that may help ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback